Rubella

Table of Contents

  1. Overview
  2. Epidemiology
  3. Pathophysiology
  4. Etiology and Risk Factors
  5. Clinical Presentation
  6. Diagnosis
  7. Treatment
  8. Complications
  9. Prognosis
  10. Prevention
  11. Recent Research and Advances
  12. Research Papers
  13. Connections
  14. Featured Videos

1. Overview

Rubella — also called “German measles” or the “3-day measles” — is a contagious viral illness caused by the Rubella virus, a single-stranded positive-sense RNA virus belonging to the genus Rubivirus within the family Togaviridae. Despite its popular nickname, rubella is not related to measles (rubeola) at all — the two diseases are caused by entirely different viruses and are not even in the same viral family. The “German measles” label is a historical artifact from 19th-century German physicians who first described it as a separate entity from measles and scarlet fever. The “3-day measles” nickname comes from the hallmark pink-red rash that typically fades within about three days — far shorter than the rash of true measles, which persists for around a week.

In healthy children and adults, postnatal rubella is usually a mild, self-limiting illness: a brief prodrome of low-grade fever, swollen lymph nodes, and achy joints, followed by a fleeting pink rash. Most people recover completely within a week and think little more of it. But rubella harbors a dangerous secret that makes it one of the most medically important vaccine-preventable infections on earth: infection during pregnancy — especially in the first trimester — can devastate the developing baby.

Congenital Rubella Syndrome (CRS) is the cluster of severe birth defects that results when the rubella virus crosses the placenta and infects the fetus during the critical window of organogenesis. Cataracts, deafness, heart defects, intellectual disability — the toll of CRS on babies born before the vaccine era was enormous. Before the MMR vaccine was introduced in the United States in 1969, epidemic years brought tens of thousands of babies with CRS. The American rubella epidemic of 1964–1965 alone resulted in an estimated 20,000 infants born with CRS and triggered more than 11,000 fetal deaths. The vaccine ended that. Today, endemic rubella transmission has been eliminated from the entire WHO Region of the Americas. Yet globally, rubella and CRS remain serious problems wherever vaccination programs are incomplete, and imported cases serve as a reminder that “eliminated” and “eradicated” are not the same thing.

This page explains both faces of rubella — the ordinary mild illness in postnatal life and the serious threat it poses to an unborn child — in plain language for ordinary people, with the goal of making the why-behind-the-vaccine crystal clear.

2. Epidemiology

Rubella is a human-only infection — there is no animal reservoir — and it circulates exclusively through person-to-person respiratory transmission. Before vaccination was widespread, rubella was endemic in every country, with epidemics recurring every six to nine years as enough new susceptible children accumulated. The burden was not in rubella itself, which was mild, but in CRS: every epidemic wave left a fresh cohort of babies with permanent damage.

The global burden today is sharply split along vaccination coverage lines. In countries with strong two-dose MMR programs — most of the Americas, Western Europe, Australia, and parts of Asia — rubella has been dramatically reduced or eliminated. The WHO Region of the Americas was certified rubella-free in 2015, a landmark achievement. The United States declared the elimination of endemic rubella in 2004. In contrast, rubella remains endemic across much of sub-Saharan Africa, Southeast Asia, and the Western Pacific, where vaccination coverage is incomplete. The WHO estimates approximately 100,000 babies are born with CRS each year worldwide, almost entirely in these under-vaccinated regions.

Even in countries that have eliminated endemic transmission, rubella cases still occur through importation — travelers bringing the virus from endemic regions. In the United States, virtually every rubella case detected in the past two decades has been import-associated. This is why maintaining high vaccination coverage matters even in countries that have “won” against rubella domestically: a gap in coverage is an invitation for an imported case to find a chain of susceptible people.

Before vaccination in the US, there were approximately 12.5 million rubella cases per year, with approximately 20,000 CRS cases in epidemic years. The MMR vaccine essentially ended that. Today, the US reports only a handful of cases annually, nearly all in unvaccinated individuals or foreign-born adults from countries without rubella vaccination programs.

3. Pathophysiology

Rubella enters the body via the respiratory tract, where the virus infects cells of the nasopharyngeal mucosa. From there it spreads to regional lymph nodes and then seeds the bloodstream — a phase called viremia — before it reaches the skin and other target organs to produce the rash and systemic symptoms we recognize as rubella.

The virus has a striking affinity for actively dividing cells, which is the key to understanding why it is so dangerous to the fetus. During the first trimester, the developing baby’s organs are being constructed from scratch — cells are dividing at extraordinary rates to form the heart, eye, ear, brain, and limb structures. When rubella infects fetal cells during this critical window, it disrupts mitosis (cell division), causes cell death, and impairs the normal differentiation of tissues. The result is malformation of whichever organ was under construction at the moment of infection. The earlier the infection occurs, the more organ systems are simultaneously vulnerable, and the more devastating the damage.

Rubella also infects the placental vasculature, causing localized tissue damage that can impair nutrient delivery to the fetus and contribute to intrauterine growth restriction. Unlike some other congenital infections, rubella typically does not spread to the fetal brain through the cerebrospinal fluid route; instead, it reaches the fetal circulation directly via the placenta and disseminates from there.

In postnatal rubella, the immune response is central to both the symptoms and the recovery. The maculopapular rash is largely immune-mediated rather than a direct result of viral destruction of skin cells — it reflects the body’s inflammatory response to viral antigens. Similarly, the joint inflammation (arthralgia and arthritis) that is so common in adult women reflects immune complex deposition in synovial tissue. The lymphadenopathy that precedes the rash — especially the characteristic swelling of postauricular and suboccipital nodes behind the ear and at the base of the skull — is the immune system mounting its response in the lymph nodes draining the site of initial infection.

After recovery, rubella-specific IgG antibody provides lifelong immunity. Natural infection generally induces more durable immunity than vaccination, although both are highly protective.

4. Etiology and Risk Factors

Rubella is caused by a single agent: the Rubella virus (Rubivirus rubellae), the sole member of its genus. It is a single-stranded, positive-sense RNA virus in the family Togaviridae. There is only one known serotype, which means immunity to one strain is immunity to all strains worldwide — a feature that makes a single universal vaccine far more practical than is the case with viruses like influenza, which mutate rapidly.

Transmission occurs via respiratory droplets and direct contact with respiratory secretions. Rubella is moderately contagious — less so than measles or chickenpox, but sufficient to spread readily in settings like schools, households, and workplaces when susceptible people are present. An infected person is contagious from about one week before the rash appears until about one week after the rash fades, meaning they are spreading the virus before they or anyone around them knows they are sick.

The groups at highest risk include:

In countries that have eliminated endemic transmission, imported rubella cases cluster predominantly in young adult immigrants from unvaccinated populations — a pattern that highlights the ongoing importance of screening rubella immunity at prenatal visits and vaccinating susceptible women postpartum.

5. Clinical Presentation

Rubella has two entirely different clinical pictures depending on when the infection occurs: postnatal rubella (acquired infection in a child or adult) and congenital rubella syndrome (infection of the fetus in the womb). Both deserve careful attention, but CRS is by far the more serious of the two.

Postnatal (Acquired) Rubella

After an incubation period of 14 to 21 days (average about 17 days), postnatal rubella typically begins with a prodrome lasting one to five days:

The rash then appears, typically starting on the face and forehead and spreading cephalocaudally (downward) to the trunk and extremities over one to three days. It is a maculopapular rash — flat pink-to-red spots and slightly raised bumps — that can look faintly similar to measles but is generally paler, less confluent, and shorter-lived. As the rash spreads downward onto the trunk, it typically begins to fade from the face, so that the face clears as the body breaks out. The rash lasts about three days and then fades without the skin peeling that sometimes follows measles.

Forchheimer spots — small, discrete red petechiae (tiny pinpoint bleeds) on the soft palate — are sometimes seen in the prodromal period. They are considered pathognomonic of rubella (found in no other condition), but appear in only about 20% of cases, so their absence does not rule rubella out.

Arthralgia and arthritis are the most common complication of postnatal rubella in adults, especially adult women. Up to 70% of adult women with rubella develop joint pain (arthralgia) or frank joint swelling (arthritis), particularly in the small joints of the fingers, wrists, and knees. The joint involvement typically begins around the time of the rash and resolves within days to a few weeks, though it occasionally drags on for months. Joint symptoms are less common in children and men.

In children, postnatal rubella is often so mild as to be inapparent — an estimated 20 to 50% of infections produce no symptoms at all. Yet even silent infections produce viremia and the same period of contagiousness, which is one reason rubella spread so readily before vaccination.

Congenital Rubella Syndrome (CRS)

CRS is what makes rubella a disease that the medical world takes profoundly seriously despite the mildness of postnatal illness. When a pregnant woman becomes infected, the virus can cross the placenta and infect the fetus. The risk and severity of fetal damage are tightly linked to gestational age at the time of infection:

The classic presentation of CRS was first described by the Australian ophthalmologist Norman McAlister Gregg in 1941, who noticed a cluster of infants with congenital cataracts born shortly after a rubella epidemic and connected the dots. The Gregg triad remains the textbook hallmark of CRS:

  1. Cataracts — unilateral or bilateral; often dense enough to block vision entirely; typically noticed as a white reflex in the pupil (leukocoria)
  2. Congenital cardiac defects — most commonly patent ductus arteriosus (PDA) and pulmonary artery stenosis; ventricular and atrial septal defects also occur
  3. Sensorineural hearing loss — the most common single manifestation of CRS overall, resulting from damage to the cochlea; may be the only defect when maternal infection occurs later in pregnancy (17–20 weeks); often bilateral and severe

Beyond the classic triad, CRS can cause a wide range of additional defects:

Some CRS manifestations are late-onset, appearing months to years after birth:

Sensorineural deafness deserves special emphasis because it is the most common single CRS defect and is frequently missed in early infancy without systematic hearing screening. A baby who was exposed to rubella in utero but appears otherwise healthy should receive careful audiological evaluation, because deafness may be the only permanent legacy of a relatively late-pregnancy maternal infection.

6. Diagnosis

Diagnosis of rubella can sometimes be made clinically when the complete picture is present — the characteristic cephalocaudal rash, short duration, and especially the distinctive postauricular and suboccipital lymphadenopathy that appears before the rash. However, because many rash illnesses look similar, and because the consequences of missing rubella in a pregnant woman are so severe, laboratory confirmation is strongly recommended whenever rubella is suspected, especially in a pregnant patient or anyone with potential exposure to a pregnant woman.

Serological Testing

Rubella-specific IgM antibody is the cornerstone of confirming acute infection. IgM becomes detectable from the time of rash onset and remains positive for about four weeks. A positive IgM in the right clinical context confirms recent infection. IgG seroconversion — a four-fold or greater rise in IgG titer between a sample taken acutely and a sample taken two to three weeks later — also confirms recent infection. Serology is also used to screen immune status: a single positive IgG titer (without the clinical picture of acute illness) indicates past infection or vaccination and therefore immunity; a negative IgG identifies a susceptible person.

PCR

Reverse-transcriptase PCR (RT-PCR) can detect rubella virus RNA in throat swabs, blood (buffy coat), or urine and is most sensitive in the first few days after rash onset. PCR is particularly valuable for confirming cases quickly when immediate public health action is needed (such as when an unvaccinated pregnant woman is exposed), and for genotyping the virus to track transmission chains.

Diagnosis in Pregnancy and Prenatal Diagnosis

When a pregnant woman has potential exposure to rubella or presents with a compatible rash illness, serological testing is performed urgently. If acute maternal infection is confirmed, amniocentesis (sampling amniotic fluid) and fetal blood sampling can be performed to detect rubella-specific IgM in fetal blood or rubella RNA by PCR in amniotic fluid, but these carry procedural risks, and a negative test cannot completely rule out fetal infection.

Diagnosis of CRS in Newborns

In a newborn with suggestive features (cataracts, heart defect, deafness, or blueberry muffin rash), CRS is confirmed by detecting rubella-specific IgM in newborn blood (IgM does not cross the placenta, so its presence in a newborn means the baby made it themselves in response to infection), by viral culture, or by PCR from nasopharyngeal secretions or urine. Newborns with CRS can shed rubella virus in nasopharyngeal secretions and urine for months after birth and must be considered infectious to susceptible caregivers, especially rubella-seronegative pregnant women, for at least the first year of life.

7. Treatment

There is no antiviral treatment for rubella. No medication has been shown to shorten the illness, reduce the severity of the rash, or — crucially — prevent the virus from crossing the placenta once a pregnant woman is infected. Management of postnatal rubella is entirely supportive:

The use of immune globulin (IG) after exposure in a pregnant woman who cannot receive the vaccine (because MMR is a live vaccine, contraindicated in pregnancy) is sometimes considered but has a very limited evidence base. IG may reduce the clinical symptoms of rubella in an exposed susceptible pregnant woman but does not reliably prevent viremia or fetal infection and should not be offered as a dependable safeguard against CRS. Its use should be reserved for situations where termination of pregnancy would not be considered under any circumstances.

Management of Congenital Rubella Syndrome

CRS has no cure, but the disabilities it causes can be identified early and managed to maximize the child’s quality of life and developmental potential. Management is inherently multidisciplinary:

8. Complications

Complications of postnatal rubella are uncommon in children but become more frequent and more significant in adults:

The most consequential outcome of rubella in any epidemiological sense is Congenital Rubella Syndrome. In a pregnant woman, CRS is the primary threat — rubella in the mother is trivial while rubella in the fetus is potentially catastrophic. The full spectrum of CRS defects, including the Gregg triad (cataracts, cardiac defects, deafness), microcephaly, intellectual disability, and late-onset diabetes and thyroid disease, is described in the Clinical Presentation section above.

9. Prognosis

For postnatal rubella in children, the prognosis is excellent. The illness is brief, self-limiting, and complications are rare. Most children recover completely within a week and have no long-term sequelae. Lifelong immunity follows natural infection.

For postnatal rubella in adults, the prognosis is still good overall, but the burden is greater: arthralgia and arthritis cause significant short-term disability in adult women, and rare complications like encephalitis carry real mortality risk. Full recovery is the rule, but the illness is considerably more disruptive than it is in children.

For rubella infection during pregnancy, the prognosis depends almost entirely on gestational age. Infection in the first 12 weeks carries an approximately 85% chance of a baby with CRS — a devastating risk. After 20 weeks, the risk is very low. The outlook for fetuses exposed in the second trimester occupies the middle ground, with sensorineural deafness being the most common isolated late outcome.

For children born with CRS, the prognosis depends on which organs are affected and how severely. Surgically correctable defects like cataracts and PDA can be repaired, and if vision and hearing are established early through appropriate intervention, developmental outcomes are substantially better. Severe microcephaly and global developmental disability represent a much more challenging picture. Late-onset complications (diabetes, thyroid disease) require lifelong management. With comprehensive early intervention, many CRS survivors live productive lives, but the caregiving burden on families is considerable.

10. Prevention

Rubella is among the most vaccine-preventable infectious diseases on earth. Because postnatal rubella in the person infected is usually mild, the entire rationale for vaccination is to protect fetuses from CRS by eliminating the virus from the community.

The MMR Vaccine

The measles-mumps-rubella (MMR) vaccine is a live attenuated combination vaccine. Two doses are standard in the US: the first at 12 to 15 months and the second at 4 to 6 years. Two doses provide approximately 95 to 99% effectiveness against rubella — among the highest efficacy rates of any vaccine. The MMR vaccine is also safe: decades of post-licensure surveillance involving hundreds of millions of doses have found no credible evidence of links to autism or other feared outcomes. The most common reaction is a mild fever and transient rash in the days following vaccination, reflecting the attenuated immune response — this is not rubella and is not contagious.

Prenatal Rubella Screening

Because the MMR vaccine is a live vaccine and is contraindicated during pregnancy, the strategy for protecting fetuses begins before pregnancy. Rubella immune status (rubella IgG) should be checked at the first prenatal visit of every pregnancy. If a woman is found to be rubella-seronegative during pregnancy, she cannot be vaccinated until after delivery. Rubella-seronegative women must receive MMR vaccine as soon as possible after delivery, ideally before leaving the hospital, to protect future pregnancies. They are advised to avoid becoming pregnant for four weeks after MMR vaccination as a standard precautionary margin.

Vaccination of Women of Childbearing Age

Any woman of childbearing age who has not received two doses of MMR and is not already known to be immune (by serology or documented prior infection) should be vaccinated, provided she is not pregnant at the time. Immigrant women from countries without rubella vaccination programs deserve particular attention, as they are overrepresented among the small number of rubella-susceptible adults who might become pregnant in countries that have otherwise eliminated the disease.

Global Elimination Goals

The WHO has set targets for rubella elimination across all WHO regions. Full global elimination would permanently protect every unborn baby from CRS. The obstacle is not scientific (the vaccine works extremely well) but programmatic: reaching every country with two-dose MMR coverage requires sustained funding, political will, and cold-chain infrastructure in settings where those are difficult to guarantee. A critical lesson from low-coverage settings is the vaccination paradox: partial immunization at coverage below about 80% can paradoxically increase CRS rates by reducing childhood exposure, shifting infections to older unimmunized women of childbearing age. This is a strong argument for achieving high coverage quickly rather than gradually.

Prevention Summary

11. Recent Research and Advances

Despite the dramatic success of vaccination in eliminating endemic rubella from much of the world, rubella research continues on several important fronts.

Surveillance and molecular epidemiology remain active. As endemic transmission is interrupted in more regions, the remaining cases are nearly all importation-linked, and genetic sequencing of circulating strains allows epidemiologists to trace precisely where imported cases originate. This surveillance has documented the ongoing global circulation of specific rubella genotypes in Africa, Asia, and Eastern Europe, providing real-time intelligence about where vaccination gaps remain.

CRS surveillance and long-term outcomes in surviving CRS patients are yielding new information. Research over the past decade has better characterized the rate of late-onset CRS complications — particularly the substantially elevated risk of diabetes mellitus and thyroid disease in CRS survivors compared to the general population. There is also renewed interest in understanding the molecular mechanisms by which rubella disrupts fetal cell division and differentiation, particularly the virus’s interaction with apoptosis pathways (programmed cell death) in dividing fetal cells.

Vaccine coverage and the elimination paradox are actively studied. Studies from regions introducing rubella vaccines for the first time have documented the risk of paradoxically increasing CRS rates at low coverage levels. This well-documented “vaccination paradox” is a central reason WHO emphasizes that rubella vaccines must achieve high population coverage quickly, not gradually, and it remains a live area of public health research in high-burden settings.

Long-term durability of vaccine-induced immunity is being assessed as the first large MMR cohorts reach 50–60 years of age. Evidence so far suggests that vaccine-induced rubella immunity is remarkably durable, with most vaccine recipients retaining protective antibody levels decades after vaccination, which is reassuring for the long-term goal of maintaining herd protection even as direct exposure to circulating wild-type virus becomes rare.

12. References & Research

Historical Background

Rubella was recognized as a distinct illness from measles and scarlet fever by German physicians in the 18th and 19th centuries — giving rise to the informal name “German measles.” The pivotal moment in understanding rubella came in 1941 when the Australian ophthalmologist Norman McAlister Gregg published his landmark observation that congenital cataracts in infants were associated with maternal rubella during pregnancy, establishing the concept of teratogenic viral infection. The subsequent 1964–1965 rubella epidemic in the United States caused an estimated 20,000 CRS cases, over 11,000 fetal deaths, and 2,000 neonatal deaths, crystallizing the urgency of vaccine development. The rubella vaccine was licensed in the US in 1969 and combined with measles and mumps into MMR in 1971. The Americas declared rubella and CRS eliminated in 2015 — a historic achievement made possible by universal MMR vaccination programs.

Key Research Papers

  1. Reef SE, Strebel P, Dabbagh A, Gacic-Dobo M, Cochi S. Progress toward control of rubella and prevention of congenital rubella syndrome — worldwide, 2009. J Infect Dis. 2011;204(Suppl 1):S24–S31. PMID: 21666157. DOI: 10.1093/infdis/jir166
  2. Banatvala JE, Brown DW. Rubella. Lancet. 2004;363(9415):1127–1137. PMID: 15064032. DOI: 10.1016/S0140-6736(04)15897-2
  3. Miller E, Cradock-Watson JE, Pollock TM. Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet. 1982;2(8302):781–784. PMID: 6127560. DOI: 10.1016/S0140-6736(82)90847-5
  4. Reef SE, Redd SB, Abernathy E, Zimmerman L, Icenogle JP. The epidemiological profile of rubella and congenital rubella syndrome in the United States, 1998–2004. Clin Infect Dis. 2006;43(Suppl 3):S111–S117. PMID: 16998776. DOI: 10.1086/505945
  5. Cutts FT, Robertson SE, Diaz-Ortega JL, Samuel R. Control of rubella and congenital rubella syndrome (CRS) in developing countries, Part 1: burden of disease from CRS. Bull World Health Organ. 1997;75(1):55–68. PMID: 9141748
  6. Duszak RS. Congenital rubella syndrome — major review. Optometry. 2009;80(1):36–43. PMID: 19111257. DOI: 10.1016/j.optm.2008.08.011
  7. Best JM. Rubella. Semin Fetal Neonatal Med. 2007;12(3):182–192. PMID: 17337363. DOI: 10.1016/j.siny.2007.01.017
  8. Edlich RF, Winters KL, Long WB 3rd, Gubler KD. Rubella and congenital rubella (German measles). J Long Term Eff Med Implants. 2005;15(3):319–328. PMID: 15897612. DOI: 10.1615/JLongTermEffMedImplants.v15.i3.80
  9. World Health Organization. Rubella vaccines: WHO position paper, July 2020. Wkly Epidemiol Rec. 2020;95(29):306–324. PMID: 32659057
  10. Gregg NM. Congenital cataract following German measles in the mother. Trans Ophthalmol Soc Aust. 1941;3:35–46. (Landmark paper — first description of CRS; search: Gregg rubella congenital cataract historical)
  11. Reef SE, Plotkin SA. Rubella vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Vaccines. 7th ed. Elsevier; 2018. (Search: rubella vaccine MMR efficacy prevention)
  12. Plotkin SA. The history of rubella and rubella vaccination leading to elimination. Clin Infect Dis. 2006;43(Suppl 3):S164–S168. Search: rubella Americas elimination WHO 2015

Research Papers

The following PubMed searches link directly to current, peer-reviewed literature on rubella and congenital rubella syndrome. Each opens a live PubMed query in a new tab so you can explore the most recent studies on a given aspect of the disease.

  1. Rubella epidemiology and prevention
  2. Congenital rubella syndrome (CRS)
  3. Rubella in pregnancy and fetal risk
  4. MMR vaccine efficacy and safety
  5. Rubella virus biology and pathogenesis
  6. CRS sensorineural hearing loss
  7. Rubella global elimination WHO
  8. Rubella diagnosis IgM IgG serology
  9. CRS cataracts and cardiac defects (Gregg triad)
  10. Rubella arthritis in adults
  11. Rubella vaccination paradox low coverage
  12. CRS late complications diabetes thyroid

Connections

Back to Table of Contents